190 related articles for article (PubMed ID: 27566315)
1. Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
Sato H; Naito T; Ishida T; Kawakami J
Eur J Clin Pharmacol; 2016 Dec; 72(12):1463-1470. PubMed ID: 27566315
[TBL] [Abstract][Full Text] [Related]
2. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
3. Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.
Naito T; Tashiro M; Yamamoto K; Ohnishi K; Kagawa Y; Kawakami J
Eur J Clin Pharmacol; 2012 Oct; 68(10):1411-8. PubMed ID: 22441315
[TBL] [Abstract][Full Text] [Related]
4. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
5. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
[TBL] [Abstract][Full Text] [Related]
6. Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics.
Nakatsugawa E; Naito T; Shibata K; Kitajima R; Kawakami J
Fundam Clin Pharmacol; 2024 Jun; 38(3):596-605. PubMed ID: 38192190
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone.
Naito T; Takashina Y; Yamamoto K; Tashiro M; Ohnishi K; Kagawa Y; Kawakami J
J Clin Pharmacol; 2011 Nov; 51(11):1529-38. PubMed ID: 21209234
[TBL] [Abstract][Full Text] [Related]
8. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
9. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
11. Grapefruit juice enhances the exposure to oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
13. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
[TBL] [Abstract][Full Text] [Related]
14. Elevation of cytokine levels in cachectic patients with prostate carcinoma.
Pfitzenmaier J; Vessella R; Higano CS; Noteboom JL; Wallace D; Corey E
Cancer; 2003 Mar; 97(5):1211-6. PubMed ID: 12599227
[TBL] [Abstract][Full Text] [Related]
15. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?
Scheede-Bergdahl C; Watt HL; Trutschnigg B; Kilgour RD; Haggarty A; Lucar E; Vigano A
Clin Nutr; 2012 Feb; 31(1):85-8. PubMed ID: 21855185
[TBL] [Abstract][Full Text] [Related]
16. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of controlled-release oxycodone in patients with cancer pain].
Nakamura K; Kokubun H; Komatsu T; Matoba M; Hoka S; Yago K
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1449-53. PubMed ID: 17876144
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.
Söderberg Löfdal KC; Andersson ML; Gustafsson LL
Drugs; 2013 May; 73(6):533-43. PubMed ID: 23605691
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning.
Han J; Meng Q; Shen L; Wu G
Lipids Health Dis; 2018 Jan; 17(1):14. PubMed ID: 29338749
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer.
Dülger H; Alici S; Sekeroğlu MR; Erkog R; Ozbek H; Noyan T; Yavuz M
Int J Clin Pract; 2004 Jun; 58(6):545-9. PubMed ID: 15311551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]